SIS-302AA is under clinical development by Sisaf and currently in Phase II for Alopecia Areata. According to GlobalData, Phase II drugs for Alopecia Areata have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SIS-302AA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SIS-302AA overview

SIS-302-AA is under development for the treatment of autoimmune alopecia. The therapeutic candidate is administered through topical route and is being developed based on Bio-Courier technology.

Sisaf overview

Sisaf is a biopharmaceutical company that develops ribonucleic acid (RNA) therapeutics for rare diseases. The company develops therapeutics using bio-courier and ribonucleic acid (RNA) delivery technologies. Its pipeline products include SIS-101-ADO treats autosomal dominant osteopetrosis; SIS-102-ACH targets achondroplasia; SIS-401-PACA for solid tumors and pancreatic cancer; SIS-402-SBC treats secondary cancer. Its partnered pipeline products include SIS-302-AA treats alopecia; SIS-201-CD and SIS-202-CDC, which targets Type II Corneal Dystrophy. Sisaf is headquartered in Belfast, the UK.

For a complete picture of SIS-302AA’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.